Christopher S Kirk, 30Thousand Oaks, CA

2003015, Aug 14, 2003

Sep 23, 2002

10/254004

Robert Wisotzkey - Oakland CA, US
Christopher Kirk - Millbrae CA, US

A01K067/027
C12N005/06

800/018000, 435/354000, 435/320100

The present invention relates to compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruption in a CTSG. The present invention also provides methods of identifying agents that modulate CTSG expression and function, useful models, and potential treatments for various disease states and disease conditions.

2003015, Aug 21, 2003

Sep 23, 2002

10/254087

Robert Wisotzkey - Oakland CA, US
Christopher Kirk - Millbrae CA, US

A01K067/027
C12N005/06

800/018000, 435/354000

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CTSZ gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

2006019, Aug 31, 2006

Feb 28, 2006

11/365789

Mark Bennett - Moraga CA, US
Christopher Kirk - Millbrae CA, US
Susan Demo - San Francisco CA, US

Proteolix, Inc. - South San Francisco CA

A61K 38/54

424094200, 514002000

Improved regimens for administering proteasome inhibitors are described, wherein proteasome inhibition is more sustained relative to certain current regimens which permit substantial recovery of proteasome activity between doses of inhibitor.

2006027, Nov 30, 2006

Jul 13, 2006

11/457438

Robert Wisotzkey - San Francisco CA, US
Christopher Kirk - Millbrae CA, US

A01K 67/027

800018000

The present disclosure relates to compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising disruption in a CTSG. The present disclosure also provides methods of identifying agents that modulate CTSG expression and function, useful models, and potential treatments for various disease states and disease conditions.

2011023, Sep 29, 2011

Oct 21, 2009

13/125292

Christopher J. Kirk - San Francisco CA, US
Susan D. Demo - San Francisco CA, US
Mark K. Bennett - Moraga CA, US

A61K 38/07
A61K 33/24
A61P 35/00
A61P 35/02
A61P 35/04
A61P 31/00
A61P 37/02

4242771, 514 193, 514 196, 514 194, 514 195, 514 198, 424649, 514 219

The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.

2013003, Feb 7, 2013

Nov 11, 2010

13/509226

Christopher J. Kirk - San Francisco CA, US
Jing Jiang - San Jose CA, US

A61K 38/06
A61P 35/04

514 198

The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics

2022026, Aug 25, 2022

Sep 23, 2021

17/482699

- Thousand Oaks CA, US
Alana Lerner - San Francisco CA, US
Christopher J. Kirk - San Francisco CA, US
Eric Lowe - Moraga Town CA, US
Tracey Lin - Union City CA, US

A61K 38/07
A61K 38/04
A61K 38/08
A61K 31/426
A61K 31/4745
A61K 31/506
A61K 38/06
A61K 31/427
A61K 31/454
A61K 31/4545
A61K 31/5025
A61K 31/5377
A61K 45/06
C07K 5/083
C07K 5/107

This disclosure provides methods of treating a cancer in a patient using a peptide epoxyketone proteasome inhibitor in combination with a PIM kinase inhibitor.

2021023, Aug 5, 2021

Dec 21, 2020

17/129573

- Thousand Oaks CA, US
Jeremiah DEGENHARDT - San Mateo CA, US
Andrea LOEHR - San Francisco CA, US
Kevin KWEI - Mountain View CA, US
Christopher J. KIRK - San Francisco CA, US

C12Q 1/6886
G01N 33/574

Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.